Magnetic Nanoparticle Facilitated Rapid Mass Production of High Affinity Polymeric Materials (nanoMIPs) for Protein Recognition and Biosensing

Subrayal M Reddy,Andrei N. Stephen,Mark A. Holden,Sarah Dennison
DOI: https://doi.org/10.1039/d4bm00990h
2024-10-11
Biomaterials Science
Abstract:Molecularly imprinted polymers (MIPs) have been investigated extensively for broad applications in diagnostics, imaging and therapeutics due to their antibody-like specificity, high stability, low-cost and rapid production when compared with biological antibodies. Yet their widescale adoption and commercial viability is limited due to low yields and relatively lengthy preparations of current methods. We report the novel application of protein functionalised magnetic nanoparticles (MNPs) to enable the rapid mass production of nanoMIPs for protein recognition. Aldehyde functionalised MNP (MNP@CHO) precursor was synthesised using a one pot microwave method in less than 20 minutes resulting in 330 mg yield for a 30 mL reaction volume. The MNP@CHO (10mg) was subsequently functionalised with 600 μg of a target template protein giving MNP@protein. In the presence of N-hydroxymethylacrylamide (NHMA) functional monomer and N,N'-methylene bisacrylamide as crosslinker, the MNP@protein particles served as a nucleant for nanoMIP mass production in a 20 minutes synthesis process. Subsequently, the nanoMIPs could be harvested with sonication and then using a magnet, the MNP@protein could be recycled and re-used at least 5 times for further nanoMIP production cycles. In general, 10 mg of MNP@protein produced 10 mg of nanoMIP with a 20% drop in yield over the 5 synthesis cycles. For the bovine haemoglobin nanoMIP the KD was determined to be 3.47 x 10-11 M, a binding affinity rivalling values found for monoclonal antibodies. We also demonstrate that the methodology is generic by producing high affinity nanoMIPs for other proteins including albumin, lysozyme and SARS-CoV-2 recombinant protein. We therefore present a facile route to produce nanoMIPs in large industrially relevant quantities (100s of mg) and at short timescales (within a day). Our method offers realistic opportunities for industry to adopt such materials as an antibody replacement technology in diagnostics, biological extraction and therapeutics.
materials science, biomaterials
What problem does this paper attempt to address?